Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bayer A G Ord (OP:BAYZF)

56.89 UNCHANGED

Streaming Delayed Price Updated: 9:34 AM EDT, Aug 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	21,137
Open	56.89
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	56.89
Today's Range	56.89 - 56.89
52wk Range	29.80 - 61.38
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin

July 28, 2026

From Bayer

Via Business Wire

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

July 23, 2026

From Bayer

Via Business Wire

Performance

YTD	+26.6%	+26.6%
1 Month	-1.6%	-1.6%
3 Month	+26.1%	+26.1%
6 Month	+3.4%	+3.4%
1 Year	+90.1%	+90.1%

More News

Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials

July 17, 2026

From Bayer

Via Business Wire

Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming

July 14, 2026

From Bayer

Via Business Wire

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials

July 07, 2026

From Bayer

Via Business Wire

Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart

July 02, 2026

From Bayer

Via Business Wire

Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon

July 01, 2026

From Bayer

Via Business Wire

Bayer and Iambic Collaborate to Advance Drug Discovery with AI

June 22, 2026

From Bayer

Via Business Wire

Bayer Completes Acquisition of Perfuse Therapeutics

June 17, 2026

From Bayer

Via Business Wire

Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief

June 16, 2026

From Bayer

Via Business Wire

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

June 15, 2026

From Bayer

Via Business Wire

Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business

June 09, 2026

From Bayer

Via Business Wire

Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

June 08, 2026

From Bayer

Via Business Wire

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

June 05, 2026

From Bayer

Via Business Wire

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

June 02, 2026

From Bayer

Via Business Wire

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

May 30, 2026

From Bayer

Via Business Wire

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

May 21, 2026

From Bayer

Via Business Wire

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

May 21, 2026

From Bayer

Via Business Wire

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

May 19, 2026

From Bayer

Via Business Wire

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer

May 18, 2026

From Bayer

Via Business Wire

AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer

May 15, 2026

From Bayer

Via Business Wire

Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement

May 15, 2026

From Bayer

Via Business Wire

Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities

May 13, 2026

From Bayer

Via Business Wire

Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

May 07, 2026

From Bayer

Via Business Wire

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

May 06, 2026

From Bayer

Via Business Wire

Frequently Asked Questions

Is Bayer A G Ord publicly traded?

Yes, Bayer A G Ord is publicly traded.

What exchange does Bayer A G Ord trade on?

Bayer A G Ord trades on the OTC Traded

What is the ticker symbol for Bayer A G Ord?

The ticker symbol for Bayer A G Ord is BAYZF on the OTC Traded

What is the current price of Bayer A G Ord?

The current price of Bayer A G Ord is 56.89

When was Bayer A G Ord last traded?

The last trade of Bayer A G Ord was at 08/06/26 09:34 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.